Kinetics and regulation of site-specific endonucleolytic cleavage of human IGF-II mRNAs

Human insulin-like growth factor II (IGF-II) mRNA can be cleaved at a specific site in its 4 kb long 3'-UTR. This yields a stable 3' cleavage product of 1.8 kb consisting of a 3'-UTR and a poly(A) tail and an unstable 5' cleavage product containing the IGF-II coding region. After...

Full description

Saved in:
Bibliographic Details
Published inNucleic acids research Vol. 29; no. 17; pp. 3477 - 3486
Main Authors van Dijk, E L, Sussenbach, J S, Holthuizen, P E
Format Journal Article
LanguageEnglish
Published England Oxford Publishing Limited (England) 01.09.2001
Oxford University Press
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Human insulin-like growth factor II (IGF-II) mRNA can be cleaved at a specific site in its 4 kb long 3'-UTR. This yields a stable 3' cleavage product of 1.8 kb consisting of a 3'-UTR and a poly(A) tail and an unstable 5' cleavage product containing the IGF-II coding region. After cleavage, the 5' cleavage product is targeted to rapid degradation and consequently is no longer involved in IGF-II protein synthesis. Cleavage is therefore thought to provide an additional way to control IGF-II gene expression. In this paper the kinetics and the efficiency of cleavage of IGF-II mRNAs are examined. The cleavage efficiency of IGF-II mRNAs carrying four different leaders (L1-L4) is enhanced in the highly structured leaders L1 and L3. Additionally, under standard cell culture conditions cleavage is a slow process that only plays a limited role in destabilisation and translation of the IGF-II mRNAs. However, in human Hep3B cells and CaCo2 cells which express IGF-II endogenously, cleavage is upregulated 3-5-fold at high cell densities. Regulated endonucleolytic cleavage of IGF-II mRNAs is restricted to cells in which IGF-II expression is related to specific cell processes.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
To whom correspondence should be addressed. Tel: +31 30 2538966; Fax: +31 30 2539035; Email: p.holthuizen@med.uu.nl
ISSN:1362-4962
0305-1048
1362-4962
DOI:10.1093/nar/29.17.3477